3 Signs Myriad Genetics' High-Growth Days Are Over
Myriad Genetics (NASDAQ: MYGN) used to be the creme de la creme of the genetic testing industry. It had healthy profit margins, a growing business, and was well-known among investors and health professionals. But the party was busted up in 2015.
While the company's technology platform was enabled by incredible advances in biotech, genomic tools have continued to get faster, better, and cheaper over time. That has given rise to formidable competition. And though not an existential threat on its own, the new competitors brought with them a business model completely opposite to that of the genetic testing pioneer. Turns out, the market really likes the new way of doing business.
The company has been racing to play catch-up -- through acquisitions and new product expansions -- and so far Wall Street is eating it up. Myriad Genetics stock is up 120% in 2017. However, investors that dig deeper will see signs that its high-growth days are over.
Source: Fool.com
Myriad Genetics Aktie
Aufgrund von 4 Buy-Einschätzungen und 3 Sell-Einschätzungen ist die Stimmung bezüglich der Myriad Genetics Aktie ziemlich ausgeglichen.
Obwohl das Kursziel für Myriad Genetics bei 21 € liegt, was unter dem aktuellen Kurs von 22.6 € ist, zeigt sich ein Potenzial von -7.08%.
